Session ID: 

Emerging Trends: Life Sciences, Payers and Value-Based Care

1:25pm - 1:55pm Tuesday, February 12
Orlando - Rosen Centre
Rosen Centre Grand Ballroom C
Extra Fee


As healthcare transforms from volume to value-based reimbursement, life sciences companies and payers are also beginning to partner and explore value-based programs that tie reimbursement to the value/outcomes a therapy can deliver.

In this session, a senior industry consultant teams with a pharmaceutical executive versed in data and partnership to discuss emerging trends, challenges, and opportunities in RWD analytics, and the evolution of value-based programs in healthcare.

Learning Objectives:

• What is RWD? Why is it important to life sciences companies and their customers? And, specifically, what role will it play in value-based programs?
• What are the current barriers to designing and operationalizing value-based programs between life sciences companies and payers?
• What are the partnership opportunities and necessary capabilities/technologies that can accelerate the design, implementation, and scaling of value-based programs?

This session is part of a special program called HIMSS19 Pharma Forum. Extra fees and separate registration is required.


Data Strategy & Partnerships Lead,
Merck Center For Observational and Real-World Evid
Managing Director, Life Sciences,
Deloitte Consulting


Chief Quality, Chief Clin Transformation Officer
Clinical Engineering Professional
Life Sciences Professionals